COMETRIQ (cabozantinib) Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Progressive, Unresectable Locally

20-12-2013 Business Wire HealthComments (0)

CometriqExelixisPharmaceutical

Exelixis, Inc. (NASDAQ:EXEL) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion of the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC). The proposed indication also states that for patients in whom Rearranged during Transfection (R

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top